Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
13 nov. 2023 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023 ...
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
13 nov. 2023 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 ...
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
07 nov. 2023 16h01 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic...
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
06 nov. 2023 16h01 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company...
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
06 nov. 2023 07h30 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company...
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
02 nov. 2023 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
27 oct. 2023 09h25 HE
|
Acumen Pharmaceuticals, Inc.
- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of...
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
04 oct. 2023 08h00 HE
|
Acumen Pharmaceuticals, Inc.
Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included...
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
19 sept. 2023 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
06 sept. 2023 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...